Cargando…
Pretreatment Out-of-Pocket Expenses for Presumptive Multidrug-Resistant Tuberculosis Patients, India, 2016–2017
In India, under the National Tuberculosis Elimination Programme, the government provides free treatment for multidrug-resistant tuberculosis; however, many patients seek care elsewhere, which is costly. To determine those out-of-pocket expenses, we interviewed 40 presumptive patients and found that...
Autores principales: | Rathi, Priya, Shringarpure, Kalpita, Unnikrishnan, Bhaskaran, Chadha, Vineet Kumar, Acharya, Vishak, Nair, Abirami, Sagili, Karuna D., Shastri, Suresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181943/ https://www.ncbi.nlm.nih.gov/pubmed/32310069 http://dx.doi.org/10.3201/eid2605.181992 |
Ejemplares similares
-
Patient treatment pathways of multidrug-resistant tuberculosis cases in coastal South India: Road to a drug resistant tuberculosis center
por: Rathi, Priya, et al.
Publicado: (2021) -
Loss-To-Follow-Up on Multidrug Resistant Tuberculosis Treatment in Gujarat, India: The WHEN and WHO of It
por: Shringarpure, Kalpita S., et al.
Publicado: (2015) -
COVID-19 Pandemic: Need of the Hour – A Course Correction, Restructuring & Review of our Policies – An Indian Perspective
por: Acharya, K. Vishak, et al.
Publicado: (2021) -
Cost-effectiveness of GeneXpert and LED-FM for diagnosis of pulmonary tuberculosis: A systematic review
por: Sagili, Karuna D., et al.
Publicado: (2018) -
“When Treatment Is More Challenging than the Disease”: A Qualitative Study of MDR-TB Patient Retention
por: Shringarpure, Kalpita S., et al.
Publicado: (2016)